Exocrine Pancreatic Insufficiency Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Exocrine Pancreatic Insufficiency Market is expected to gain market growth at a healthy CAGR 6% from USD 2.13 Billion to USD 3.62 Billion in the forecast period of 2022 to 2028.

Exocrine pancreatic insufficiency (EPI) is a condition in which the pancreas cannot digest food properly due to insufficient levels of digestive enzymes. EPI is commonly found in humans with Schwarzman-Diamond syndrome and cystic fibrosis. EPI is caused by the gradual loss of pancreatic cells that produce digestive enzymes. EPI interferes with normal growth, life expectancy and immune responses. Diarrhea, fatty stools, fatigue, and weight loss are the main symptoms of EPI.

Market Segments

BY DISEASE MANAGEMENT

• Nutritional management
• Pancreatic enzyme replacement therapy (PERT)
• Life style modifications approach

BY DIAGNOSIS

• Magnetic resonance imaging (MRI)
• CT scanning
• Endoscopic ultra-sonography (EUS)
• Blood tests

Key Players

• Nordmark Arzneimittel GmbH & Co. KG
• Janssen Pharmaceuticals, Inc.
• AzurRx BioPharma, Inc.
• Anthera Pharmaceuticals, Inc.
• Digestive Care, Inc.

Scope of the Report

The research study analyzes the global Exocrine Pancreatic Insufficiency industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Exocrine Pancreatic Insufficiency Market Report

1. What was the Exocrine Pancreatic Insufficiency Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Exocrine Pancreatic Insufficiency Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Exocrine Pancreatic Insufficiency Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.